CattoglioC., FacchiniG., SartoriD., AntonelliA., MiccioA., CassaniB., SchmidtM., von KalleC., HoweS., ThrasherA.J., AiutiA., FerrariG., RecchiaA., MavilioF.2007. Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood, 110:1770–1778.
5.
CozzioA., PassegueE., AytonP.M., KarsunkyH., ClearyM.L., WeissmanI.L.2003. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev., 17:3029–3035.
6.
EnssleJ., TrobridgeG.D., KeyserK.A., IronsideC., BeardB.C., KiemH.-P.2010. Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentivirus vectors. Hum. Gene Ther., 21:397–403.
7.
FeliceB., CattoglioC., CittaroD., TestaA., MiccioA., FerrariG., LuziL., RecchiaA., MavilioF.2009. Transcription factor binding sites are genetic determinants of retroviral integration in the human genome. PLoS One, e4571.
8.
Hacein-Bey-AbinaS., GarrigueA., WangG.P., SoulierJ., LimA., MorillonE., ClappierE., CaccavelliL., DelabesseE., BeldjordK., AsnafiV., MacintyreE., Dal CortivoL., RadfordI., BrousseN., SigauxF., MoshousD., HauerJ., BorkhardtA., BelohradskyB.H., WintergerstU., VelezM.C., LeivaL., SorensenR., WulffraatN., BlancheS., BushmanF.D., FischerA., Cavazzana-CalvoM.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
9.
HargroveP.W., KepesS., HanawaH., ObenauerJ.C., PeiD., ChengC., GrayJ.T., NealeG., PersonsD.A.2008. Globin lentiviral vector insertions can perturb the expression of endogenous genes in β-thalassemic hematopoietic cells. Mol. Ther., 16:525–533.
10.
HoweS.J., MansourM.R., SchwarzwaelderK., BartholomaeC., HubankM., KempskiH., BrugmanM.H., Pike-OverzetK., ChattersS.J., De RidderD., GilmourK.C., AdamsS., ThornhillS.I., ParsleyK.L., StaalF.J., GaleR.E., LinchD.C., BayfordJ., BrownL., QuayeM., KinnonC., AncliffP., WebbD.K., SchmidtM., von KalleC., GasparH.B., ThrasherA.J.2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118:3143–3150.
11.
KrivtsovA., TwomeyD., FengZ., StubbsM.C., WangY., FaberJ., LevineJ.E., WangJ., HahnW.C., GillilandD.G., GolubT.R., ArmstrongS.A.2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature, 7104:818–822.
12.
KustikovaO.S., SchiedlmeierB., BrugmanM.H., StahlhutM., BartelsS., LiZ., BaumC.2009. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis. Mol. Ther., 17:1537–1547.
13.
LewinskiM.K., YamashitaM., EmermanM., CiuffiA., MarshallH., CrawfordG., CollinsF., ShinnP., LeipzigJ., HannenhalliS., BerryC.C., EckerJ.R., BushmanF.D.2006. Retroviral DNA integration: Viral and cellular determinants of target-site selection. PLoS Pathog., 2:e60.
14.
MaruggiG., PorcelliniS., FacchiniG., PernaS.K., CattoglioC., SartoriD., AmbrosiA., SchambachA., BaumC., BoniniC., BovolentaC., MavilioF., RecchiaA.2009. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther., 17:851–856.
15.
ModlichU., NavarroS., ZychlinskiD., MaetzigT., KnoessS., BrugmanM.H., SchambachA., CharrierS., GalyA., ThrasherA.J., BuerenJ., BaumC.2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther., 17:1919–1928.
16.
MontiniE., CesanaD., SchmidtM., SanvitoF., BartholomaeC.C., RanzaniM., BenedicentiF., SergiL.S., AmbrosiA., PonzoniM., DoglioniC., Di SerioC., von KalleC., NaldiniL.2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection. J. Clin. Invest., 119:964–975.
17.
MostoslavskyG., KottonD.N., FabianA.J., GrayJ.T., LeeJ.S., MulliganR.C.2005. Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. Mol. Ther., 11:932–940.
18.
NewrzelaS., CornilsK., LiZ., BaumC., BrugmanM.H., HartmannM., MeyerJ., HartmannS., HansmannM.L., FehseB., Von LaerD.2008. Resistance of mature T cells to oncogene transformation. Blood, 112:2278–2286.
19.
SteinS., OttM.G., Schultze-StrasserS., JauchA., BurwinkelB., KinnerA., SchmidtM., KrämerA., SchwäbleJ., GlimmH., KoehlU., PreissC., BallC., MartinH., GöhringG., SchwarzwaelderK., HofmannW.K., KarakayaK., TchatchouS., YangR., ReineckeP., KühlckeK., SchlegelbergerB., ThrasherA.J., HoelzerD., SegerR., von KalleC., GrezM.2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.
20.
WangG.P., GarrigueA., CiuffiA., RonenK., LeipzigJ., BerryC., Lagresle-PeyrouC., BenjellounF., Hacein-Bey-AbinaS., FischerA., Cavazzana-CalvoM., BushmanF.D.2008. DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res., 36:e49.
